Trial Profile
A Quality of Life Study of PEGASYS (Peginterferon-Alfa2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Persistently Normal ALT Levels
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 05 Apr 2016 New trial record